Valuation: Jazz Pharmaceuticals plc

Market Cap 16.01B 14.08B 13.08B 12.03B 22.56B 1,550B 22.97B 156B 61.01B 756B 60.11B 58.81B 2,624B P/E 2026 *
18.1x
P/E 2027 * 16.3x
Enterprise Value 17.71B 15.57B 14.47B 13.31B 24.96B 1,715B 25.4B 173B 67.49B 836B 66.48B 65.04B 2,902B EV / Sales 2026 *
3.92x
EV / Sales 2027 * 3.31x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day+1.78%
1 week+5.24%
Current month+5.77%
1 month+10.69%
3 months+27.46%
6 months+51.07%
Current year+49.92%
1 week 242.11
Extreme 242.11
255.2
1 month 224.95
Extreme 224.95
255.2
Current year 156.95
Extreme 156.95
255.2
1 year 105
Extreme 105
255.2
3 years 95.49
Extreme 95.49
255.2
5 years 95.49
Extreme 95.49
255.2
10 years 86.88
Extreme 86.88
255.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Founder

-6,000 0.0096%
6/30/26 Tax

Chief Executive Officer

-4,835 0.0077%
6/30/26 Tax

General Counsel

-2,678 0.0043%
Change 5-day change 1-year change 3-year change Capi.($)
+1.78%+5.24%+117.21%+94.69% 16.01B
+1.97%+1.43%+48.44%+156.66% 1,057B
+1.42%+3.72%+53.32%+52.34% 624B
+1.43%+0.99%+34.83%+78.74% 454B
+0.14%+4.88%+32.21%+28.15% 341B
-1.07%+1.23%+35.29%+39.36% 297B
-0.82%+0.14%+15.64%+16.99% 262B
-0.49%-3.21%-28.58%-41.95% 215B
+1.49%-0.02%+20.14%+58.21% 201B
+0.40%-3.99%+15.23%+62.28% 162B
Average -0.03%+1.22%+34.37%+54.55% 363B
Weighted average by Cap. -0.52%+1.58%+35.29%+75.51%

Financials

2026 *2027 *
Net sales 4.51B 3.97B 3.69B 3.39B 6.36B 437B 6.47B 44.08B 17.19B 213B 16.94B 16.57B 739B 4.84B 4.26B 3.96B 3.64B 6.82B 469B 6.94B 47.3B 18.45B 229B 18.17B 17.78B 793B
Net income 1.02B 900M 836M 769M 1.44B 99.06B 1.47B 9.99B 3.9B 48.32B 3.84B 3.76B 168B 1.07B 939M 872M 802M 1.5B 103B 1.53B 10.43B 4.07B 50.42B 4.01B 3.92B 175B
Net Debt 1.7B 1.49B 1.39B 1.28B 2.39B 164B 2.44B 16.59B 6.47B 80.22B 6.38B 6.24B 278B 15.43M 13.57M 12.61M 11.59M 21.74M 1.49B 22.13M 151M 58.8M 729M 57.92M 56.67M 2.53B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-07-23 US$254.87 +1.78% 527,986
26-07-22 US$250.41 -1.50% 521,018
26-07-21 US$254.22 +4.42% 810,118
26-07-20 US$243.47 -1.64% 675,844
26-07-17 US$247.53 +2.21% 503,559
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
254.87USD
Average target price
266.90USD
Spread / Average Target
+4.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock